Paper30104599
Patient stratification in clinical glaucoma trials using the individual tear proteome.
Nättinen J and 6 others. Sci Rep, 2018. Cited by 15 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Patient stratification in clinical glaucoma trials using the individual tear proteome. Papers, record 30104599. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30104599
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Benzalkonium Compounds | Major topic |
| Glaucoma | Major topic |
| Preservatives, Pharmaceutical | Major topic |
| Proteome | Major topic |
| Tears | Major topic |
| Aged | |
| Antihypertensive Agents | |
| Female | |
| Humans | |
| Latanoprost | |
| Male | |
| Middle Aged | |
| Prostaglandins F |
Source PubMed
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28,918,083 | Topical fluorometholone treatment and desiccating stress change inflammatory protein expression in tears. | Ocul Surf | 2018 | https://conductscience.org/library/papers/28918083 | PubMed |
| 2 | 22,300,579 | Quantitative analysis of proteins in the tear fluid of patients with diabetic retinopathy. | J Proteomics | 2012 | https://conductscience.org/library/papers/22300579 | PubMed |
| 3 | 27,041,987 | Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials. | Clin Ophthalmol | 2016 | https://conductscience.org/library/papers/27041987 | PubMed |
| 4 | 23,518,768 | Ocular inflammation and corneal permeability alteration by benzalkonium chloride in rats: a protective effect of a myosin light chain kinase inhibitor. | Invest Ophthalmol Vis Sci | 2013 | https://conductscience.org/library/papers/23518768 | PubMed |
| 5 | 21,030,416 | Association of tear proteins with Meibomian gland disease and dry eye symptoms. | Br J Ophthalmol | 2011 | https://conductscience.org/library/papers/21030416 | PubMed |
| 6 | 27,436,115 | Proteomics analysis of human tears from aqueous-deficient and evaporative dry eye patients. | Sci Rep | 2016 | https://conductscience.org/library/papers/27436115 | PubMed |
| 7 | 20,553,122 | IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. | Curr Med Res Opin | 2010 | https://conductscience.org/library/papers/20553122 | PubMed |
| 8 | 17,022,631 | Secreted proteome profiling in human RPE cell cultures derived from donors with age related macular degeneration and age matched healthy donors. | J Proteome Res | 2006 | https://conductscience.org/library/papers/17022631 | PubMed |
| 9 | 22,124,706 | Differential protein expression in tears of patients with primary open angle and pseudoexfoliative glaucoma. | Mol Biosyst | 2012 | https://conductscience.org/library/papers/22124706 | PubMed |
| 10 | 27,398,637 | Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). | Expert Opin Drug Metab Toxicol | 2016 | https://conductscience.org/library/papers/27398637 | PubMed |
| 11 | 25,925,459 | Personalized medicine: Time for one-person trials. | Nature | 2015 | https://conductscience.org/library/papers/25925459 | PubMed |
| 12 | 20,546,237 | Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. | Acta Ophthalmol | 2010 | https://conductscience.org/library/papers/20546237 | PubMed |
| 13 | 11,711,191 | Personalized medicine: revolutionizing drug discovery and patient care. | Trends Biotechnol | 2001 | https://conductscience.org/library/papers/11711191 | PubMed |
| 14 | 17,460,253 | Benzalkonium chloride induces dephosphorylation of Myosin light chain in cultured corneal epithelial cells. | Invest Ophthalmol Vis Sci | 2007 | https://conductscience.org/library/papers/17460253 | PubMed |
| 15 | 14,667,241 | Vision related quality of life and topical glaucoma treatment side effects. | Health Qual Life Outcomes | 2003 | https://conductscience.org/library/papers/14667241 | PubMed |
| 16 | 24,138,574 | Mass spectrometric protein maps for biomarker discovery and clinical research. | Expert Rev Mol Diagn | 2013 | https://conductscience.org/library/papers/24138574 | PubMed |
| 17 | 22,736,608 | iTRAQ quantitative proteomics in the analysis of tears in dry eye patients. | Invest Ophthalmol Vis Sci | 2012 | https://conductscience.org/library/papers/22736608 | PubMed |
| 18 | 23,733,261 | Proteomic analysis revealed the altered tear protein profile in a rabbit model of Sjögren's syndrome-associated dry eye. | Proteomics | 2013 | https://conductscience.org/library/papers/23733261 | PubMed |
| 19 | 19,770,725 | Mass spectrometry-based proteomic analyses in contact lens-related dry eye. | Cornea | 2009 | https://conductscience.org/library/papers/19770725 | PubMed |
| 20 | 24,282,230 | Tear proteomic analysis of patients with type 2 diabetes and dry eye syndrome by two-dimensional nano-liquid chromatography coupled with tandem mass spectrometry. | Invest Ophthalmol Vis Sci | 2014 | https://conductscience.org/library/papers/24282230 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40,002,800 | Precision in Tear Fluid Biomarker Discovery: Quantitative Proteomic Profiling of Small-Volume, Individual Samples Using Capillary Tube Collection. | Biomedicines | 2025 | https://conductscience.org/library/papers/40002800 | PubMed |
| 36,401,306 | Glaucoma-TrEl: A web-based interactive database to build evidence-based hypotheses on the role of trace elements in glaucoma. | BMC Res Notes | 2022 | https://conductscience.org/library/papers/36401306 | PubMed |
| 35,897,711 | Clinical Tear Fluid Proteomics-A Novel Tool in Glaucoma Research. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35897711 | PubMed |
| 35,774,416 | Biofluids manipulation methods for liquid biopsy in minimally-invasive assays. | MethodsX | 2022 | https://conductscience.org/library/papers/35774416 | PubMed |
| 35,216,421 | Comparison of Different Mass Spectrometry Workflows for the Proteomic Analysis of Tear Fluid. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35216421 | PubMed |
| 35,050,124 | Proteomic Analysis of Tears and Conjunctival Cells Collected with Schirmer Strips Using timsTOF Pro: Preanalytical Considerations. | Metabolites | 2021 | https://conductscience.org/library/papers/35050124 | PubMed |
| 33,759,206 | Mass spectrometry-based tear proteomics for noninvasive biomarker discovery. | Mass Spectrom Rev | 2022 | https://conductscience.org/library/papers/33759206 | PubMed |
| 32,714,642 | Comparison of Capillary and Schirmer Strip Tear Fluid Sampling Methods Using SWATH-MS Proteomics Approach. | Transl Vis Sci Technol | 2020 | https://conductscience.org/library/papers/32714642 | PubMed |
Genes26
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30104599
GET https://conductscience.org/api/papers/v1/30104599/references?page=2